A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

Trial Profile

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Bladder cancer; Breast cancer; Cervical cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 2 Mar 2018 to 19 Jan 2018.
    • 19 Jun 2017 Planned primary completion date changed from 2 Mar 2018 to 19 Jan 2018.
    • 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top